-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Figure 1: Qilu Pharmaceutical's latest approved product situation Source: NMPA official website Qufluorouricoside tablets are first copied It is understood that Qufluorourucride tablets are quefluorourialine (FTD) and hydrochloric acid tyridine (TPI) an oral compounding agent consisting of 1:0.5 molar ratio for the treatment of metastatic colorectal cancer, originally developed by Dapeng, Japan, and imported by NMPA in August 2019.
Figure 2: Qufluorouricoside tablets declared listed enterprises Source: Minet MED2.0 China Drug Review Database Minet data show that the current declaration of quefluorouruclein tablets imitation listed enterprises have 2, zhengTianqing first declaration, but finally by Qilu preempted to take the first imitation.
the first evaluation of the hydrochloric acid Fasshudir injection of hydrochloric acid Fashudir injection of the adaptive disorder to improve and prevent the cobweb subcavity hemorrhage after cerebrovascular spasms and caused by cerebral ischemia symptoms, in China's urban public hospitals, county-level public hospitals, urban community centers and townships Terminal sales at health hospitals (China's public medical institutions) reached nearly 1 billion in 2015 and growth has declined in recent years, with less than 500 million in 2019, but the product ranks top2 in the list of surrounding vascular dilation drug injections, and the market position remains strong.
the competitive landscape, Tianjin Red Day Pharmaceuticals led the market with 57.62 percent in the first half of 2020, with Qilu Pharmaceuticals' market share of less than 1 percent.
Table 1: Declaration of hydrochloric acid Fashudir injection consistency evaluation supplementary application of the enterprise situation Source: Minet MED2.0 China Drug Review Database At present, in addition to Qilu's first review, the enterprises reporting the hydrochloric acid Fashudir injection consistency evaluation supplementary application also have Yangzijiang, Yuandong, Bert, Red Day and other 5, Abao Pharmaceuticals according to the new classification declaration is also under review and approval.
THE third domestic figure 3: Currently obtained hydrochloric acid Praxo tablet approval of the enterprise situation Source: Minenet one-click retrieval of hydrochloric acid Plaxo tablets for the treatment of idiopathic Parkinson's disease signs and symptoms, alone (no L-doba) or in combination with L-Doba.
2019, prakso hydrochloride tablets topped the list with sales of nearly 700 million yuan in top-20, according to top-level anti-Parkinson's drug products in China's public medical facilities.
In the current domestic market Grigg Ingeham occupies more than 90% of the market, Beijing New Pharmaceuticals in 2018 won the first imitation (October 2020 through the consistent evaluation), stone medicine in January 2020 with 4 types of imitations approved and treated as the same, Qilu this time is also approved according to 4 types of imitations, become the third domestic "approved and evaluated" enterprises.
source: Mi Net database, NMPA official website review data statistics as of January 5, 2021, if there are errors, please point out.
original title: "Heavy" Qilu approved! Anti-tumor drug first imitation, injection first over-evaluation, 700 million varieties of domestic third